Abstract: The present disclosure provides novel crystalline forms of a compound that acts as a ?-arrestin effector, processes for preparing novel crystalline and amorphous forms of a compound that acts as a ?-arrestin effector and uses thereof.
Type:
Grant
Filed:
February 6, 2015
Date of Patent:
December 13, 2016
Assignee:
Trevena, Inc.
Inventors:
Ritesh Sanghvi, Gregory Alcorn, Graham Richard Lawton, Meiki Yu, Matthew Ronsheim, Jiaher Tian, Shao Hong Zhou, Yuriy B. Kalyan
Abstract: Prolonged or extended release of bioactive protein is achieved using an affinity-based approach which exploits the specific binding of Src homology 3 (SH3) domain with short proline-rich peptides. Specifically, methylcellulose was modified with SH3-binding peptides (MC-peptide) with either a weak affinity or strong affinity for SH3. Controlled release of chondroitinase ABC (ChABC) is also described.
Abstract: The present application describes organic compounds of Formula (I) and pharmaceutical compositions thereof, and their use for the treatment, prevention and/or amelioration of diseases, particularly bacterial infections.
Type:
Grant
Filed:
May 30, 2014
Date of Patent:
November 15, 2016
Assignee:
Novartis AG
Inventors:
Simon Bushell, Matthew J. Lamarche, Jennifer Leeds, Lewis Whitehead
Abstract: The present invention provides compositions comprising the component of fermented wheat germ extract (“FWGE”) active in reducing, inhibiting or preventing the proliferation of cancer cells and/or tumors, and methods of making and using such compositions. The active component from FWGE comprises polypeptides having a molecular weight in the range of about 5-100 kiloDaltons (kD), for example, a molecular weight in the range of about 12-50 kD. Exemplary polypeptides from FWGE determined to be active in reducing, inhibiting or preventing the proliferation of cancer cells and/or tumors are listed in Table 1.
Type:
Grant
Filed:
May 20, 2010
Date of Patent:
November 1, 2016
Assignee:
The Regents of the University of California
Inventors:
Joseph Tuscano, Derick Lau, Robert O'Donnell, Yunpeng Ma
Abstract: The present invention relates to a method for purifying lactoferrin, which is a pharmacologically important milk protein having various physiological activities, from a secretory fluid containing lactoferrin.
Abstract: Novel hybrid polymers are disclosed that have a structure represented by the following wherein Abiotic oligomer, Polypeptide, X, Y, and R1 are as described herein. The methods to prepare the hybrid polymers via novel oxazolidinyl compounds are also described.
Type:
Grant
Filed:
May 20, 2014
Date of Patent:
October 4, 2016
Assignee:
New York University
Inventors:
Kent Kirshenbaum, Paul Levine, Timothy Craven
Abstract: The instant invention relates to polyethylene glycol-based dendrons, otherwise known as PEGtide dendrons, compositions thereof and methods of use.
Type:
Grant
Filed:
November 14, 2011
Date of Patent:
October 4, 2016
Assignee:
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Inventors:
Patrick J. Sinko, Jieming Gao, Yashveer Singh, Xiaoping Zhang, Matthew S. Palombo, Stanley Stein
Abstract: Melanocortin receptor-specific cyclic heptapeptides of the formula Z-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Y??(II) or a pharmaceutically acceptable salt thereof, where Z, Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6, Xaa7 and Y are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes.
Type:
Grant
Filed:
July 11, 2014
Date of Patent:
October 4, 2016
Assignee:
Palatin Technologies, Inc.
Inventors:
Yi-qun Shi, Shubh D. Sharma, John H. Dodd, Wei Yang
Abstract: The present invention provides a novel class of macrocyclic compounds, which are useful as cysteine protease inhibitors. Also provided are novel intermediates and methods of preparing the compounds. The invention also provides pharmaceutical compositions comprising the compounds. The compounds and compositions are useful in methods of treating or preventing one or more diseases associated with cysteine protease activity, particularly those associated with calpain activity.
Type:
Grant
Filed:
March 12, 2014
Date of Patent:
September 6, 2016
Assignees:
UNIVERSITY OF CANTERBURY, LINCOLN UNIVERSITY, DOUGLAS PHARMACEUTICALS LIMITED
Inventors:
Andrew David Abell, James Morriss Coxon, Matthew Alan Jones, Stephen Brian McNabb, Axel Thomas Neffe, Steven Geoffrey Aitken, Blair Gibb Stuart, Janna Marie Nikkel, Joanna Kimberley Duncan, Mutita Klanchantra, James David Morton, Roy Bickerstaffe, Lucinda Jane Goodricke Robertson, Hannah Yun Young Lee, Matthew Stewart Muir
Abstract: The present invention relates to a sustained-release drug composition consisting essentially of microparticles of a peptide as the active substance and a biocompatible water-soluble polymer, in particular peptide as meianocortin receptor ligand. The present invention relates also to an injection formulation comprising the sustained-release drug composition suspended in an injection medium.
Abstract: A viscoelastic hydrogel based on a protein hetero-assembled with a polymer is provided. The protein cannot self-assemble with itself and the polymer cannot self-assemble with itself. The protein has a first association sequence (1stA) and a first spacer (1stSp). The polymer has a second association sequence (2ndA) and a second spacer (2ndSp). The first association sequence and the second association sequence are physically cross-linked to interact with each other with a 1:1 known and specific stoichiometry to form a three dimensional scaffold. The protein is represented by {1stA(1stSp)}x1stA, where x is ?2, and the polymer is represented by {2ndA(2ndSp)}y2ndA, where y?2.
Type:
Grant
Filed:
April 20, 2015
Date of Patent:
July 26, 2016
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Sarah C. Heilshorn, Widya Mulyasasmita, Lei Cai
Abstract: A peptide targeted conjugate is disclosed. The conjugate comprises: (a) an isolated or a synthetic targeting peptide of less than 15 amino acid residues in length, comprising an amino acid sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NOs: 1, 2 and 3; and (b) a component, to which the targeting peptide is conjugated, the component being selected from the group consisting of a drug delivery vehicle, an anti-cancer drug, a micelle, a nanoparticle, liposomes, a polymer, a lipid, an oligonucleotide, a peptide, a polypeptide, a protein, a cell, an imaging agent, and a labeling agent. The conjugate may further comprise an anti-cancer agent encapsulated within the drug delivery vehicle. Compositions and methods of treating cancer are also disclosed.
Abstract: The purpose of the present invention is to provide a cross-linked peptide containing a novel non-peptide cross-linked structure, and a method for synthesizing the same. A cross-linked peptide having a novel non-peptide cross-linked structure, a useful intermediate for synthesizing the cross-linked peptide, and a method for synthesizing the novel cross-linked peptide and the intermediate are provided. The cross-linked peptide is characterized by having an —NR— bond in the cross-linked structure. By using the method for synthesizing the cross-linked peptide, a cross-link can be freely designed and an change can be freely made to a cross-link.
Abstract: The purpose of the present invention is to provide a cross-linked peptide containing a novel non-peptide cross-linked structure, and a method for synthesizing the same. A cross-linked peptide having a novel non-peptide cross-linked structure, a useful intermediate for synthesizing the cross-linked peptide, and a method for synthesizing the novel cross-linked peptide and the intermediate are provided. The cross-linked peptide is characterized by having an —NR— bond in the cross-linked structure. By using the method for synthesizing the cross-linked peptide, a cross-link can be freely designed and an change can be freely made to a cross-link.
Abstract: The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.
Type:
Grant
Filed:
February 26, 2015
Date of Patent:
June 7, 2016
Assignee:
Cardiorentis AG
Inventors:
Veselin Mitrovic, Hartmut Luss, Wolf-Georg Forssmann, Markus Meyer, Klaus Dohler
Abstract: Multicomponent compositions and methods of use thereof are disclosed herein. Some embodiments of the present invention include multicomponent compositions comprising a first component and a second component, where the first component comprises a notch influencing molecule and the second component comprises a GPCR targeted molecule. Kits comprising the multicomponent composition are also disclosed. Methods for providing the multicomponent composition to one or more cells are additionally provided. Further embodiments include methods of using the multicomponent composition such as, for example, methods of administering the multicomponent composition and method of treating organisms (such as mammals) using the multicomponent composition.
Type:
Grant
Filed:
February 16, 2012
Date of Patent:
June 7, 2016
Assignee:
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
Abstract: Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, specificity, resistance to degradation desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides result from structure-based rational design relating to antimicrobial peptide V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Some peptides contain one or more (or all) amino acids in the D configuration.
Type:
Grant
Filed:
August 17, 2012
Date of Patent:
May 24, 2016
Assignee:
The Regents of the University of Colorado, a body corporate
Abstract: The present invention relates to a method for producing a transfer factor. The method comprises the following steps: freezing and thawing of peripheral-blood leukocytes, dialysis, tangential ultrafiltration, identification and quantification using high-resolution, molecular-exclusion liquid chromatography, and in vitro biological validation. The resulting product is suitable for medical use.
Abstract: The described invention provides kinase inhibiting compositions containing a therapeutic amount of a therapeutic inhibitor peptide that inhibits at least one kinase enzyme, methods for treating an inflammatory disorder whose pathophysiology comprises inflammatory cytokine expression, and methods for treating an inflammatory disorder whose pathophysiology comprises inflammatory cytokine expression using the kinase inhibiting compositions.